Go Back   NeuroTalk Support Groups > Health Conditions M - Z > Parkinson's Disease

Parkinson's Disease Tulip

Low-Dose Naltrexone’s in Fatigued Patients with Parkinson’s

Thread Tools Display Modes
Unread 05-10-2012, 07:51 AM   #1
Senior Member
olsen's Avatar
Join Date: Aug 2006
Posts: 1,792
Default Low-Dose Naltrexone’s in Fatigued Patients with Parkinson’s

Abstract #13: Low-Dose Naltrexone’s Tolerability and Effects in Fatigued Patients with Parkinson’s Disease: An Open-Label Study
Thomas Guttuso, Jr., Naomi Salins, and David Lichter
State University of New York at Buffalo
Introduction: One third of idiopathic Parkinson’s disease (IPD) patients report fatigue as their most disabling symptom, and 58% consider fatigue to be one of their three most disabling symptoms. The use of low-dose naltrexone (LDN), 4.5 mg qhs, has been anecdotally reported to improve fatigue in IPD.
Methods: We are examining the tolerability and effective- ness of LDN in patients with parkinsonism in an ongoing open- label trial. Fatigue and motor symptoms in the “On” state are being assessed at baseline and every 4 months over 1 year using the Parkinson Fatigue Scale (PFS-16) and the Unified Parkinson’s Disease Rating Scale (UPDRS), respectively. Global Satisfaction of Treatment is also being assessed. We report here on the changes in fatigue and motor scores among the 4 IPD subjects who were fatigued at baseline, defined as a score of e 53 on the PFS-16. We also compare the fatigue changes with those from previous trials in fatigued IPD and multiple sclerosis (MS) patients.
Results: Eight subjects have been enrolled since January 2009. The 4 IPD subjects who were fatigued at baseline have experienced a mean 22% reduction in PFS-16 scores (range 13–30%) and a 15% increase in total UPDRS “On” scores after 8 months of LDN therapy. Mean Global Satisfaction of Treat- ment at 8 months was 8.75 on the 10-point scale. No side effects have been associated with LDN therapy among the 8 subjects. Based on previous randomized controlled trials (RCTs), the only effective therapy for fatigue in IPD has been methylphenidate, which showed a 16% decrease in fatigue from baseline. The three therapies demonstrating effectiveness in treating fatigue in MS patients in RCTs have been amanta- dine, modafinil, and aspirin, which decreased fatigue by 24%, 20%, and 18% from baseline, respectively. Modafinil was shown to be ineffective in treating fatigue in IPD.
Conclusions: In this small, open-label trial, LDN therapy was well tolerated and was associated with equivalent reduc- tions in fatigue compared with historical benchmarks. These observed reductions in fatigue are unlikely to have been a function of any perceived improvements to motor symptoms, because UPDRS scores slightly worsened over the 8-month trial, as expected in this progressive disease.
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot

The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Low Dose Naltrexone??? betsykk Reflex Sympathetic Dystrophy (RSD and CRPS) 9 10-23-2012 08:59 AM
Has anyone used Low Dose Naltrexone for RSD? Millerprof Reflex Sympathetic Dystrophy (RSD and CRPS) 17 10-13-2012 09:18 PM
Low Dose Naltrexone rose_thorn98 Chronic Pain 15 11-24-2011 02:57 AM
low dose Naltrexone-LDN tinglytoes Medications & Treatments 3 02-06-2010 09:04 PM
Low Dose Naltrexone bluedahlia Parkinson's Disease 1 04-05-2009 03:58 PM

All times are GMT -5. The time now is 10:34 AM.
Brought to you by the fine folks who publish mental health and psychology information at Psych CentralMental Health Forums

The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider. Always consult your doctor before trying anything you read here.

Powered by vBulletin • Copyright ©2000 - 2016, Jelsoft Enterprises Ltd.

All posts copyright their original authors • Community GuidelinesTerms of UsePrivacy Policy
NeuroTalk Archives